Tags

Type your tag names separated by a space and hit enter

Inhibitory Effects of Siegesbeckia orientalis Extracts on Advanced Glycation End Product Formation and Key Enzymes Related to Metabolic Syndrome.
Molecules. 2017 Oct 21; 22(10)M

Abstract

Metabolic syndrome typically includes Type 2 diabetes associated with hyperglycemia, central obesity, dyslipidemia and hypertension. It is highly related to oxidative stress, formation of advanced glycated end products (AGEs) and key enzymes, such as carbohydrate digesting enzymes like pancreatic α-amylase and intestinal α-glucosidase, pancreatic lipase and angiotensin I-converting enzyme (ACE). This study used an in vitro approach to assess the potential of four extracts of Siegesbeckia orientalis linne on key enzymes relevant to metabolic syndrome. In this research, S. orientailis was firstly extracted by ethanol. The ethanol extract (SE) was then partitioned sequentially with hexane, ethyl acetate and methanol, and these extracts were named SE-Hex, SE-EA and SE-MeOH, respectively. The experimental results showed that SE-EA had the highest total phenolic content (TPC, 76.9 ± 1.8 mg/g) and the total flavonoids content (TFC, 5.3 ± 0.3 mg/g). This extract exhibited the most significant antioxidant activities, including DPPH radical-scavenging capacity (IC50 = 161.8 ± 2.4 μg/mL), ABTS radical-scavenging capacity (IC50 = 13.9 ± 1.5 μg/mL) and reducing power. For anti-glycation activities, SE-EA showed the best results in the inhibition of AGEs, as well as inhibitory activities against α-glucosidase (IC50 = 362.3 ± 9.2 μg/mL) and α-amylase (IC50 = 119.0 ± 17.7 μg/mL). For anti-obesity activities, SE-EA indicated the highest suppression effect on pancreatic lipase (IC50 = 3.67 ± 0.52 mg/mL). Finally, for anti-hypertension activity, SE-EA also demonstrated the strongest inhibitory activity on ACE (IC50 = 626.6 ± 15.0 μg/mL). Close relationships were observed among the parameters of TPC, antioxidant activities, inhibitory activities on α-amylase, α-glucosidase, lipase and ACE (R > 0.9). Moderate correlations were found among the parameters of TFC, antioxidant activities, and suppression of dicarbonyl compounds formation (R = 0.5-0.9). Taken together these in vitro studies reveal the therapeutic potential of SE-EA extract in the prevention and treatment of metabolic disorders.

Authors+Show Affiliations

Division of Cardiology, E-Da Hospital, Kaohsiung 82445, Taiwan. ed102600@edah.org.tw.Graduate Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung 84001, Taiwan. ed107312@gmail.com. Department of Obstetrics & Gynecology, E-Da Hospital/I-Shou University, Kaohsiung 82445, Taiwan. ed107312@gmail.com.Department of Obstetrics & Gynecology, E-Da Hospital/I-Shou University, Kaohsiung 82445, Taiwan. ed101779@edah.org.tw.Department of Nutrition, I-Shou University, Kaohsiung 82445, Taiwan. fen153848@gmail.com.Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, E-Da Hospital/I-Shou University, Kaohsiung 82445, Taiwan. shihwei8888@gmail.com.Department of Nutrition Therapy, E-Da Hospital, Kaohsiung 82445, Taiwan. ed103549@edah.org.tw.Department of Nutrition, I-Shou University, Kaohsiung 82445, Taiwan. r9620239@yahoo.com.tw.Department of Nutrition, I-Shou University, Kaohsiung 82445, Taiwan. lisa10143018@gmail.com.Graduate Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung 84001, Taiwan. jyhoung@isu.edu.tw. Department of Nutrition, I-Shou University, Kaohsiung 82445, Taiwan. jyhoung@isu.edu.tw.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29065451

Citation

Hung, Wei-Chin, et al. "Inhibitory Effects of Siegesbeckia Orientalis Extracts On Advanced Glycation End Product Formation and Key Enzymes Related to Metabolic Syndrome." Molecules (Basel, Switzerland), vol. 22, no. 10, 2017.
Hung WC, Ling XH, Chang CC, et al. Inhibitory Effects of Siegesbeckia orientalis Extracts on Advanced Glycation End Product Formation and Key Enzymes Related to Metabolic Syndrome. Molecules. 2017;22(10).
Hung, W. C., Ling, X. H., Chang, C. C., Hsu, H. F., Wang, S. W., Lee, Y. C., Luo, C., Lee, Y. T., & Houng, J. Y. (2017). Inhibitory Effects of Siegesbeckia orientalis Extracts on Advanced Glycation End Product Formation and Key Enzymes Related to Metabolic Syndrome. Molecules (Basel, Switzerland), 22(10). https://doi.org/10.3390/molecules22101785
Hung WC, et al. Inhibitory Effects of Siegesbeckia Orientalis Extracts On Advanced Glycation End Product Formation and Key Enzymes Related to Metabolic Syndrome. Molecules. 2017 Oct 21;22(10) PubMed PMID: 29065451.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibitory Effects of Siegesbeckia orientalis Extracts on Advanced Glycation End Product Formation and Key Enzymes Related to Metabolic Syndrome. AU - Hung,Wei-Chin, AU - Ling,Xue-Hua, AU - Chang,Chi-Chang, AU - Hsu,Hsia-Fen, AU - Wang,Shih-Wei, AU - Lee,Yi-Chen, AU - Luo,Ci, AU - Lee,Yun-Tzu, AU - Houng,Jer-Yiing, Y1 - 2017/10/21/ PY - 2017/09/26/received PY - 2017/10/14/revised PY - 2017/10/16/accepted PY - 2017/10/26/entrez PY - 2017/10/27/pubmed PY - 2018/6/12/medline KW - Siegesbeckia orientalis linne KW - advanced glycation end products KW - angiotensin I-converting enzyme KW - antioxidation KW - lipase KW - α-amylase KW - α-glucosidase JF - Molecules (Basel, Switzerland) JO - Molecules VL - 22 IS - 10 N2 - Metabolic syndrome typically includes Type 2 diabetes associated with hyperglycemia, central obesity, dyslipidemia and hypertension. It is highly related to oxidative stress, formation of advanced glycated end products (AGEs) and key enzymes, such as carbohydrate digesting enzymes like pancreatic α-amylase and intestinal α-glucosidase, pancreatic lipase and angiotensin I-converting enzyme (ACE). This study used an in vitro approach to assess the potential of four extracts of Siegesbeckia orientalis linne on key enzymes relevant to metabolic syndrome. In this research, S. orientailis was firstly extracted by ethanol. The ethanol extract (SE) was then partitioned sequentially with hexane, ethyl acetate and methanol, and these extracts were named SE-Hex, SE-EA and SE-MeOH, respectively. The experimental results showed that SE-EA had the highest total phenolic content (TPC, 76.9 ± 1.8 mg/g) and the total flavonoids content (TFC, 5.3 ± 0.3 mg/g). This extract exhibited the most significant antioxidant activities, including DPPH radical-scavenging capacity (IC50 = 161.8 ± 2.4 μg/mL), ABTS radical-scavenging capacity (IC50 = 13.9 ± 1.5 μg/mL) and reducing power. For anti-glycation activities, SE-EA showed the best results in the inhibition of AGEs, as well as inhibitory activities against α-glucosidase (IC50 = 362.3 ± 9.2 μg/mL) and α-amylase (IC50 = 119.0 ± 17.7 μg/mL). For anti-obesity activities, SE-EA indicated the highest suppression effect on pancreatic lipase (IC50 = 3.67 ± 0.52 mg/mL). Finally, for anti-hypertension activity, SE-EA also demonstrated the strongest inhibitory activity on ACE (IC50 = 626.6 ± 15.0 μg/mL). Close relationships were observed among the parameters of TPC, antioxidant activities, inhibitory activities on α-amylase, α-glucosidase, lipase and ACE (R > 0.9). Moderate correlations were found among the parameters of TFC, antioxidant activities, and suppression of dicarbonyl compounds formation (R = 0.5-0.9). Taken together these in vitro studies reveal the therapeutic potential of SE-EA extract in the prevention and treatment of metabolic disorders. SN - 1420-3049 UR - https://www.unboundmedicine.com/medline/citation/29065451/Inhibitory_Effects_of_Siegesbeckia_orientalis_Extracts_on_Advanced_Glycation_End_Product_Formation_and_Key_Enzymes_Related_to_Metabolic_Syndrome_ L2 - https://www.mdpi.com/resolver?pii=molecules22101785 DB - PRIME DP - Unbound Medicine ER -